+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Enanta Pharmaceuticals Inc - logo

Enanta Pharmaceuticals is a biotechnology company that focuses on small molecule drugs for viral infections and liver diseases. Enanta’s research is currently focused on the following disease targets: Hepatitis B Virus (HBV), Non-alcoholic Steatohepatitis (NASH)/PBC and Respiratory Syncytial Virus (RSV). The company has a collaborative development and license agreement with AbbVie to develop and commercialize HCV NS3 and NS3/4A protease inhibitors. Enanta was founded in 1995 and is headquartered in Watertown, Massachusetts.

Hepatitis B (Infectious Disease) - Drugs in Development, 2021 - Product Thumbnail Image

Hepatitis B (Infectious Disease) - Drugs in Development, 2021

  • Drug Pipelines
  • September 2021
  • 654 Pages
From
Chronic Hepatitis B Virus Infection - Pipeline Insight, 2022 - Product Thumbnail Image

Chronic Hepatitis B Virus Infection - Pipeline Insight, 2022

  • Clinical Trials
  • March 2022
  • 60 Pages
From
Non-Structural Protein 5 Inhibitor - Pipeline Insight, 2022 - Product Thumbnail Image

Non-Structural Protein 5 Inhibitor - Pipeline Insight, 2022

  • Clinical Trials
  • January 2022
  • 90 Pages
From
From
Hepatitis B - Pipeline Review, H2 2020 - Product Thumbnail Image

Hepatitis B - Pipeline Review, H2 2020

  • Drug Pipelines
  • November 2020
  • 575 Pages
From
From
From
From
From
From
From
Nonalcoholic Steatohepatitis - Pipeline Insight, 2021 - Product Thumbnail Image

Nonalcoholic Steatohepatitis - Pipeline Insight, 2021

  • Clinical Trials
  • May 2021
  • 230 Pages
From
From
From
Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2020 - Product Thumbnail Image

Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2020

  • Drug Pipelines
  • July 2020
  • 1101 Pages
From
From
Loading Indicator